Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current applications for prostate-specific antigen doubling time.

Michelle L Ramírez1, Eric C Nelson, Ralph W Devere White

  • 1Department of Urology and Cancer Center, University of California at Davis, Sacramento, CA 95817, USA.

European Urology
|April 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026
Same author

Cancer statistics, 2026: Charting a course for a national cancer research agenda.

CA: a cancer journal for clinicians·2026
Same author

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.

JCO oncology practice·2025
Same author

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

Cancer research communications·2025
Same author

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.

NPJ precision oncology·2025
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Prostate-specific antigen doubling time (PSADT) offers a dynamic view of prostate cancer (PCa) aggressiveness. This marker aids in managing PCa across various stages, from diagnosis to advanced disease.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer (PCa) management relies on accurate prognostic markers.
  • Prostate-specific antigen doubling time (PSADT) reflects tumor behavior and aggressiveness.

Purpose of the Study:

  • To review the role of PSADT in PCa diagnosis, treatment, recurrence, and advanced stages.
  • To assess PSADT as a prognostic factor and its utility in PCa management.

Main Methods:

  • Literature search of PubMed using keywords related to PSADT and PCa.
  • Selection of relevant, seminal, or controversial articles with significant evidence.
  • Summarization of data on PSADT for diagnosis, characterization, and prediction of outcomes.

Main Results:

  • PSADT provides a dynamic assessment of tumor behavior and aggressiveness.

Related Experiment Videos

  • PSADT is valuable in active surveillance, post-treatment recurrence, and androgen-independent PCa.
  • PSADT is a significant prognostic factor and potential surrogate endpoint, though optimal cutoffs are debated.

    • Conclusions:

    • PSADT is a reliable predictor for PCa risk stratification.
    • PSADT is incorporated into predictive nomograms and treatment guidelines for PCa management.